½ÃÀ庸°í¼­
»óǰÄÚµå
1621550

¼¼°èÀÇ Á¾¾ç ÀýÁ¦ ½ÃÀå : ±â¼ú, Ä¡·á, ÀûÀÀÁõº° ¿¹Ãø(2025-2030³â)

Tumor Ablation Market by Technology (Cryoablation, High-Intensity Focused Ultrasound, Irreversible Electroporation Ablation), Treatment (Laparoscopic Ablation, Percutaneous Ablation, Surgical Ablation), Indication - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 182 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Á¾¾ç ÀýÁ¦ ½ÃÀåÀº 2023³â 17¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2024³â 20¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç CAGR 13.85%·Î ¼ºÀåÇϸç 2030³â¿¡´Â 44¾ï 2,000¸¸ ´Þ·¯°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Á¾¾ç ÀýÁ¦´Â °íÁÖÆÄ ÀýÁ¦, ³Ãµ¿ ÀýÁ¦, ¸¶ÀÌÅ©·ÎÆÄ ÀýÁ¦ µîÀÇ ¹æ¹ý¿¡ ÀÇÇØ ¾Ï Á¶Á÷À̳ª Á¾¾çÀ» ÆÄ±«Çϵµ·Ï ¼³°èµÈ Àúħ½À óġ¸¦ ¸»ÇÕ´Ï´Ù. Á¾¾ç ÀýÁ¦ÀÇ Çʿ伺Àº ¾Ï À¯º´·ü Áõ°¡¿Í ´õ ³·Àº ħ½ÀÀ¸·Î ºñ¿ë È¿À²ÀûÀ̰í ȯÀÚ Ä£È­ÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺À¸·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. ±× ¿ëµµ´Â Á¾¾çÇÐ, ƯÈ÷ °£¾Ï, ½ÅÀå¾Ï, Æó¾Ï, »À¾Ï µî¿¡ À̸£°í ÀÖÀ¸¸ç, ¼ö¼ú°ú ¿ÏÈ­ ÄÉ¾î ¾çÂÊÀÇ Àå¸é¿¡¼­ ºÒ°¡°áÇÑ °ÍÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¹üÀ§¿¡´Â ÁÖ·Î º´¿ø, ¼ö¼ú¼¾ÅÍ, ¾Ï Àü¹® Ŭ¸®´ÐÀÌ Æ÷ÇԵ˴ϴÙ. ½ÃÀå ¼ºÀåÀº ¿µ»ó À¯µµ ½Ã½ºÅÛ°ú ÀýÁ¦ ±â¼úÀÇ Çâ»ó°ú °°Àº ±â¼úÀû Áøº¸, ¾Ï Áõ·Ê Áõ°¡, ¿Ü·¡ ȯÀÚ ¹× ºñħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ±âÈ£ Áõ°¡¿¡ Å©°Ô ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ÃÖ½ÅÀÇ ÀáÀçÀû ±âȸ´Â Á¤È®¼ºÀ» ³ôÀ̱â À§ÇÑ AI¿Í ·Îº¸Æ½½ºÀÇ ÅëÇÕ°ú ¾Ï ÀÌȯÀ²ÀÌ ³ôÀº ½ÅÈï ½ÃÀåÀ¸·ÎÀÇ ¾îºí·¹ÀÌ¼Ç ±â¼úÀÇ È®´ë¿¡ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Æ÷ÂøÇϱâ À§ÇÑ ±ÇÀå»çÇ׿¡´Â ÇÏÀ̺긮µå ±â¼úÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ¿Í ¼¼°è À¯Åë¸ÁÀÇ È®´ë°¡ Æ÷ÇԵ˴ϴÙ. ±×·¯³ª ½ÅÈï±¹ ½ÃÀå¿¡¼­ ³·Àº ÀÎÁöµµ, ³ôÀº ¼ö¼ú ºñ¿ë, ÀáÀçÀûÀÎ ¼ö¼ú ÈÄ ÇÕº´Áõ µîÀÇ Á¦¾àÀÌ ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ´Ù¸¥ °úÁ¦¿¡´Â ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú ÀÌ·¯ÇÑ °í±Þ ÀýÂ÷¸¦ ¼öÇàÇϱâ À§ÇÑ ¼÷·ÃµÈ Àü¹®°¡ÀÇ Çʿ伺ÀÌ Æ÷ÇԵ˴ϴÙ. Çõ½Å°ú ¿¬±¸´Â ÀåºñÀÇ ¼ÒÇüÈ­ °³¼±°ú »õ·Î¿î ¿¡³ÊÁö ¹æ½Ä ޱ¸¿Í °°Àº ºÐ¾ß¿¡¼­ Ȱ¹ßÇØÁú ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀýÁ¦ ÈÄ Á¾¾ç Àç¹ßÀÇ »ý¹°ÇÐÀû ÀÌÇØ¸¦ ±í°Ô ÇÏ´Â ¿¬±¸´Â Ä¡·á ÇÁ·ÎÅäÄÝÀÇ °­È­·Î À̾îÁý´Ï´Ù. Àü¹ÝÀûÀ¸·Î, Á¾¾ç ÀýÁ¦ ½ÃÀåÀº ±Þ¼ÓÇÑ ±â¼ú Áøº¸¸¦ Ư¡À¸·Î ÇÏ´Â ¿ªµ¿ÀûÀÎ ½ÃÀåÀÌÁö¸¸, ±ÔÁ¦¿Í ÀÚ¿øÀÇ °úÁ¦¿¡ ÀÇÇØ Á¦¾àÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ Æ¯¼º»ó ¼ºÀåÀ» °¡¼ÓÇÏ°í ±âÁ¸ À庮À» ±Øº¹Çϱâ À§Çؼ­´Â Çõ½Å, ȯÀÚ Á᫐ Á¢±Ù¹ý, Àü·«Àû ÆÄÆ®³Ê½Ê¿¡ ÁßÁ¡À» µÎ¾î¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 17¾ï 8,000¸¸ ´Þ·¯
¿¹Ãø³â(2024) 20¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030) 44¾ï 2,000¸¸ ´Þ·¯
CAGR(%) 13.85%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â Á¾¾ç ÀýÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Á¾¾ç ÀýÁ¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ëÀ» ÅëÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. ºñÁî´Ï½º ±âȸ¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ÏÀÇ À¯º´·üÀÇ »ó½Â°ú È¿°úÀûÀÎ Ä¡·áÀÇ Çʿ伺
    • Á¾¾ç ÀûÃâÀ» À§ÇÑ Àúħ½À ¼ö¼ú·ÎÀÇ ½ÃÇÁÆ® Áõ°¡
    • °íµµÀÇ ¾Ï Ä¡·á¿¡ ´ëÇÑ »óȯ Á¤Ã¥ÀÇ °³¼±
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¾¾ç ÀýÁ¦ Àåºñ ¼³°èÀÇ º¹À⼺
  • ½ÃÀå ±âȸ
    • ¼¼°èÀÇ Á¾¾ç ÀýÁ¦ ±â¼úÀÇ Áøº¸
    • Á¾¾ç ÀýÁ¦¿¡ ´ëÇÑ Á¤ºÎÀÇ È£ÀÇÀû ½ÂÀÎ
  • ½ÃÀåÀÇ °úÁ¦
    • ±â±âÀÇ Ç°Áú°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á

Porter's Five Force : Á¾¾ç ÀýÁ¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Force´Â Á¾¾ç ÀýÁ¦ ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Force Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂûÀ» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç, º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Á¾¾ç ÀýÁ¦ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº Á¾¾ç ÀýÁ¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® : Á¾¾ç ÀýÁ¦ ½ÃÀå¿¡¼­ °æÀï ±¸µµ ÆÄ¾Ç

Á¾¾ç ÀýÁ¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : Á¾¾ç ÀýÁ¦ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â Á¾¾ç ÀýÁ¦ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±âº» °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÐÇÒÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå : Á¾¾ç ÀýÁ¦ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ °æ·Î¸¦ ±×¸³´Ï´Ù.

Á¾¾ç ÀýÁ¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ÀÇ ÇöÀå °­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¾Ï ÀÌȯÀ²ÀÇ »ó½Â°ú È¿°úÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺
      • Á¾¾çÀ» Á¦°ÅÇϱâ À§ÇÑ Àúħ½À ¼ö¼ú·ÎÀÇ ÀÌÇàÀÌ Áõ°¡
      • ÁøÇà¾Ï Ä¡·áÀÇ »óȯ Á¤Ã¥ÀÇ °³¼±
    • ¾ïÁ¦¿äÀÎ
      • Á¾¾ç ÀýÁ¦ ÀåÄ¡ ¼³°èÀÇ º¹À⼺
    • ±âȸ
      • ¼¼°è Á¾¾ç ÀýÁ¦ ±â¼úÀÇ ¹ßÀü
      • Á¾¾ç ÀýÁ¦¿¡ ´ëÇÑ Á¤ºÎÀÇ È£ÀÇÀû ½ÂÀÎ
    • °úÁ¦
      • ±â±âÀÇ Ç°Áú°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
    • Ä¡·á:Àúħ½À ¼ö¼úÀ» ÇÊ¿ä·Î Çϴ ȯÀÚ¿¡ ´ëÇÑ º¹°­°æ ¾îºí·¹À̼ÇÀÇ ±ÞÁõ
    • ÀûÀÀÁõ : Æó¾Ï Ä¡·á¿¡ Á¾¾ç ÀýÁ¦¸¦ »ç¿ëÇÏ´Â Á¶»ç Áõ°¡
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå Á¾¾ç ÀýÁ¦ ½ÃÀå : ±â¼úº°

  • µ¿°á¿ä¹ý
  • °í°­µµ ÃÊÁ¡½Ä ÃÊÀ½ÆÄ
  • º¹±¸ ºÒ°¡ Àü±â õ°ø ÀýÁ¦
  • ·¹ÀÌÀú Á¶Á÷ ³»¿­ ÀýÁ¦
  • ¸¶ÀÌÅ©·ÎÆÄ ¾îºí·¹À̼Ç
  • °íÁÖÆÄ ¾îºí·¹À̼Ç

Á¦7Àå Á¾¾ç ÀýÁ¦ ½ÃÀå : Ä¡·áº°

  • º¹°­°æ ¾îºí·¹À̼Ç
  • °æÇÇ ÀýÁ¦
  • ¿Ü°úÀû ÀýÁ¦

Á¦8Àå Á¾¾ç ÀýÁ¦ ½ÃÀå : ÀûÀÀÁõº°

  • À¯¹æ¾Ï
  • ½ÅÀå¾Ï
  • °£¾Ï
  • Æó¾Ï
  • Àü¸³¼±¾Ï

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ Á¾¾ç ÀýÁ¦ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Á¾¾ç ÀýÁ¦ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¾¾ç ÀýÁ¦ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
    • Medtronic, FDA ½ÂÀÎ OsteoCool 2.0 ½Ã½ºÅÛÀ¸·Î »À Á¾¾ç Ä¡·á¸¦ Çâ»ó
    • BioTraceIO°¡ ÃÊÀ½ÆÄ ±â¹ÝÀÇ BioTraceIO·Î FDAÀÇ ½ÂÀÎÀ» Ãëµæ
    • FDA°¡ Francis Medical, Inc.ÀÇ ¼öÁõ±â ÀýÁ¦ ¿ä¹ýÀÇ Vanquish¿¡ ȹ±âÀû Ä¡·áÁ¦ ÁöÁ¤À» ºÎ¿©
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Angiodynamics, Inc.
  • Bioventus LLC.
  • Boston Scientific Corp.
  • BVM Medical Limited
  • Chongqing Haifu Medical Technology Co., Ltd.
  • CONMED Corporation
  • CooperSurgical, Inc.
  • Erbe Elektromedizin GmbH
  • IceCure Medical Ltd.
  • Integra LifeSciences Corporation
  • Johnson & Johnson Services, Inc.
  • Medtronic PLC
  • Mermaid Medical A/S
  • Smith & Nephew PLC
  • Theraclion SA
JHS 25.01.02

The Tumor Ablation Market was valued at USD 1.78 billion in 2023, expected to reach USD 2.01 billion in 2024, and is projected to grow at a CAGR of 13.85%, to USD 4.42 billion by 2030.

Tumor ablation refers to minimally invasive procedures designed to destroy cancerous tissue or tumors through methods such as radiofrequency ablation, cryoablation, and microwave ablation. The necessity of tumor ablation arises from the growing prevalence of cancer and the need for less invasive, cost-effective, and patient-friendly treatment options. Its application spans oncology, particularly for liver, kidney, lung, and bone cancers, making it essential in both operational and palliative care settings. The end-use scope primarily includes hospitals, surgical centers, and specialized cancer clinics. Market growth is significantly influenced by technological advancements such as image-guidance systems and improved ablation techniques, rising cancer cases, and an increasing preference for outpatient and non-invasive procedures. Additionally, the latest potential opportunities lie in the integration of AI and robotics for precision, as well as the expansion of ablation technologies into emerging markets with high cancer rates. A recommendation to seize these opportunities includes investing in R&D for hybrid technologies and expanding distribution networks globally. However, limitations such as the lack of awareness in developing regions, high procedural costs, and potential postoperative complications could hamper market growth. Other challenging factors include stringent regulatory requirements and the need for skilled professionals to perform these advanced procedures. Innovation and research could thrive in areas like improving device miniaturization and exploring novel energy modalities. Furthermore, research into better understanding the biology of tumor recurrence post-ablation can lead to enhanced treatment protocols. Overall, the tumor ablation market is dynamic, characterized by rapid technological advancement, yet constrained by regulatory and resource challenges. The nature of the market demands a focus on innovation, patient-centric approaches, and strategic partnerships to drive growth and overcome existing barriers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.78 billion
Estimated Year [2024] USD 2.01 billion
Forecast Year [2030] USD 4.42 billion
CAGR (%) 13.85%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tumor Ablation Market

The Tumor Ablation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer and need for effective treatments
    • Increasing shift to minimally invasive surgeries to remove tumors
    • Improvements in reimbursement policies for advanced cancer treatments
  • Market Restraints
    • Complexity of designing tumor ablation devices
  • Market Opportunities
    • Advancements in tumor ablation technologies worldwide
    • Favorable government approvals for tumor ablation
  • Market Challenges
    • Concerns associated with quality and safety of the device

Porter's Five Forces: A Strategic Tool for Navigating the Tumor Ablation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tumor Ablation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tumor Ablation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tumor Ablation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tumor Ablation Market

A detailed market share analysis in the Tumor Ablation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tumor Ablation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tumor Ablation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tumor Ablation Market

A strategic analysis of the Tumor Ablation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tumor Ablation Market, highlighting leading vendors and their innovative profiles. These include Angiodynamics, Inc., Bioventus LLC., Boston Scientific Corp., BVM Medical Limited, Chongqing Haifu Medical Technology Co., Ltd., CONMED Corporation, CooperSurgical, Inc., Erbe Elektromedizin GmbH, IceCure Medical Ltd., Integra LifeSciences Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Mermaid Medical A / S, Smith & Nephew PLC, and Theraclion S. A..

Market Segmentation & Coverage

This research report categorizes the Tumor Ablation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Cryoablation, High-Intensity Focused Ultrasound, Irreversible Electroporation Ablation, Laser Interstitial Thermal Ablation, Microwave Ablation, and Radiofrequency Ablation.
  • Based on Treatment, market is studied across Laparoscopic Ablation, Percutaneous Ablation, and Surgical Ablation.
  • Based on Indication, market is studied across Breast Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, and Prostate Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer and need for effective treatments
      • 5.1.1.2. Increasing shift to minimally invasive surgeries to remove tumors
      • 5.1.1.3. Improvements in reimbursement policies for advanced cancer treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Complexity of designing tumor ablation devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in tumor ablation technologies worldwide
      • 5.1.3.2. Favorable government approvals for tumor ablation
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with quality and safety of the device
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Exponential use of laparoscopic ablation for patients requiring minimally invasive surgery
    • 5.2.2. Indication: Increasing research in using tumor ablation for treating lung cancer
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tumor Ablation Market, by Technology

  • 6.1. Introduction
  • 6.2. Cryoablation
  • 6.3. High-Intensity Focused Ultrasound
  • 6.4. Irreversible Electroporation Ablation
  • 6.5. Laser Interstitial Thermal Ablation
  • 6.6. Microwave Ablation
  • 6.7. Radiofrequency Ablation

7. Tumor Ablation Market, by Treatment

  • 7.1. Introduction
  • 7.2. Laparoscopic Ablation
  • 7.3. Percutaneous Ablation
  • 7.4. Surgical Ablation

8. Tumor Ablation Market, by Indication

  • 8.1. Introduction
  • 8.2. Breast Cancer
  • 8.3. Kidney Cancer
  • 8.4. Liver Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer

9. Americas Tumor Ablation Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Tumor Ablation Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Tumor Ablation Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Medtronic Elevates Bone Tumor Treatment with FDA-Approved OsteoCool 2.0 System
    • 12.3.2. BioTraceIO receives FDA Approval for Ultrasound-Based BioTraceIO
    • 12.3.3. FDA Grants Breakthrough Designation to Vanquish Water Vapor Ablation Therapy by Francis Medical, Inc.
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Angiodynamics, Inc.
  • 2. Bioventus LLC.
  • 3. Boston Scientific Corp.
  • 4. BVM Medical Limited
  • 5. Chongqing Haifu Medical Technology Co., Ltd.
  • 6. CONMED Corporation
  • 7. CooperSurgical, Inc.
  • 8. Erbe Elektromedizin GmbH
  • 9. IceCure Medical Ltd.
  • 10. Integra LifeSciences Corporation
  • 11. Johnson & Johnson Services, Inc.
  • 12. Medtronic PLC
  • 13. Mermaid Medical A / S
  • 14. Smith & Nephew PLC
  • 15. Theraclion S. A.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦